Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04536298 · ClinicalTrials.gov registry record · Phase 3
Vitamin D for COVID-19 Trial
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,024
- Enrollment target
NCT04536298 is a Phase 3 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 2,024 participants.
The verdict
NCT04536298, a Phase 3 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,024 participants
- Enrollment target
Study Summary
The Vitamin D for COVID-19 Trial (VIVID) is a randomized, placebo-controlled clinical trial in 2024 men and women from across the U.S. and Mongolia to investigate whether taking a daily dietary supplement of vitamin D vs. placebo for 4 weeks reduces the rate of seeking healthcare for symptoms or concerns related to COVID-19 in participants recently diagnosed with COVID-19, and reduces the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in household contacts of individuals with newly diagnosed COVID-19.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT vitamin D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,024 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04536298
The ClinicalTrials.gov registry entry for NCT04536298 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,024 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04536298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04536298 about?
NCT04536298 is a clinical study titled "Vitamin D for COVID-19 Trial". The Vitamin D for COVID-19 Trial (VIVID) is a randomized, placebo-controlled clinical trial in 2024 men and women from across the U.S. and Mongolia to investigate whether taking a daily dietary supplement of vitamin D vs. placebo for 4 weeks reduces the rate of seeking healthcare for symptoms or con...
What is the current status of trial NCT04536298?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,024 participants. The study started on 2020-12-28. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT04536298?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), vitamin D (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04536298?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.